iX Biopharma Ltd. (SGX:42C)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.191
-0.009 (-4.50%)
Mar 2, 2026, 5:04 PM SGT
809.52%
Market Cap 197.93M
Revenue (ttm) 7.23M
Net Income (ttm) -5.95M
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,692,000
Average Volume 15,346,945
Open 0.196
Previous Close 0.200
Day's Range 0.190 - 0.205
52-Week Range 0.015 - 0.250
Beta n/a
RSI 50.91
Earnings Date Feb 4, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an... [Read more]

Sector Healthcare
Founded 2004
Employees 35
Stock Exchange Singapore Exchange
Ticker Symbol 42C
Full Company Profile

Financial Performance

In fiscal year 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.

Financial Statements

News

There is no news available yet.